Combination Treatment Migraine Study

Ages

18 - 80

Location

Columbus, OH

Compensation

Up to $693

Combination Treatment Migraine Trials in Columbus

Centricity Research is currently participating in a combination treatment migraine study at our Columbus, Ohio location. A proportion of individuals receiving preventive monotherapy for migraine may continue to experience migraine attacks and migraine-related disability. Atogepant has demonstrated effectiveness in significantly reducing the number of migraine and headache days in patients with episodic migraine. Ubrogepant has been approved by the FDA for the acute treatment of migraine with or without aura in adults.

Enroll Now

Combination Treatment Migraine Clinical Trial

The purpose of this study is to evaluate the safety and tolerability of the combined use of ubrogepant 100 mg for the acute treatment of breakthrough migraine headaches in people taking atogepant 60 mg once a day for preventive treatment of migraine. You maybe be eligible to participate in this study if you:

  • Are 18 to 80 years of age
  • Have experienced migraines for 1 year or more, starting before age 50
  • Have had migraines 4-14 days per month in each of the last 3 months

Ready to Volunteer?

Volunteer today to see if you qualify for our combination treatment migraine study. Qualified volunteers may be compensated for time and travel.